老年糖尿病患者的多重用药:意大利北部人群基础研究

IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Elena Succurro, Luisa Ojeda-Fernández, Carlotta Franchi, Anna Zanovello, Laura Pierini, Alessandro Nobili, Ida Fortino, Giorgio Sesti, Marta Baviera
{"title":"老年糖尿病患者的多重用药:意大利北部人群基础研究","authors":"Elena Succurro, Luisa Ojeda-Fernández, Carlotta Franchi, Anna Zanovello, Laura Pierini, Alessandro Nobili, Ida Fortino, Giorgio Sesti, Marta Baviera","doi":"10.1007/s00592-025-02523-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the trends in chronic polypharmacy and identify predictors of polypharmacy exposure in a population residing in Lombardy region of Italy.</p><p><strong>Methods: </strong>Using an administrative health database, we identified individuals aged 65-90 years with diabetes mellitus (DM) treated with antihyperglycemic drugs from 2010 to 2022. The trend of chronic polypharmacy was assessed using the Cochran-Armitage trend test. An adjusted logistic regression model was employed to analyze predictors of polypharmacy exposure.</p><p><strong>Results: </strong>The number of older patients with DM increased from 243,160 in 2010 to 314,238 in 2022. The prevalence of polypharmacy exposure rose from 13.8% in 2010 to 15.8% in 2013, followed by a decline starting in 2014. Notably, in 2020, the prevalence dropped to 11.8%, further decreasing to 9.1% in 2021, before rising again to 11.7% in 2022. We also observed an increased use of recommended antihyperglycemic drugs over time. Significant predictors of polypharmacy exposure included advanced age, female sex, comorbidities, and use of DPP-4i, GLP-1-RA, insulin, and SGLT2-i.</p><p><strong>Conclusions: </strong>The observed decrease in polypharmacy in the latter years of the study period may reflect improvements in the management of older patients with DM, aligning with recommended therapies, particularly for those at higher risk of polypharmacy.</p>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Polypharmacy in older patients with diabetes mellitus: a population based-study of northern Italy.\",\"authors\":\"Elena Succurro, Luisa Ojeda-Fernández, Carlotta Franchi, Anna Zanovello, Laura Pierini, Alessandro Nobili, Ida Fortino, Giorgio Sesti, Marta Baviera\",\"doi\":\"10.1007/s00592-025-02523-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>To evaluate the trends in chronic polypharmacy and identify predictors of polypharmacy exposure in a population residing in Lombardy region of Italy.</p><p><strong>Methods: </strong>Using an administrative health database, we identified individuals aged 65-90 years with diabetes mellitus (DM) treated with antihyperglycemic drugs from 2010 to 2022. The trend of chronic polypharmacy was assessed using the Cochran-Armitage trend test. An adjusted logistic regression model was employed to analyze predictors of polypharmacy exposure.</p><p><strong>Results: </strong>The number of older patients with DM increased from 243,160 in 2010 to 314,238 in 2022. The prevalence of polypharmacy exposure rose from 13.8% in 2010 to 15.8% in 2013, followed by a decline starting in 2014. Notably, in 2020, the prevalence dropped to 11.8%, further decreasing to 9.1% in 2021, before rising again to 11.7% in 2022. We also observed an increased use of recommended antihyperglycemic drugs over time. Significant predictors of polypharmacy exposure included advanced age, female sex, comorbidities, and use of DPP-4i, GLP-1-RA, insulin, and SGLT2-i.</p><p><strong>Conclusions: </strong>The observed decrease in polypharmacy in the latter years of the study period may reflect improvements in the management of older patients with DM, aligning with recommended therapies, particularly for those at higher risk of polypharmacy.</p>\",\"PeriodicalId\":6921,\"journal\":{\"name\":\"Acta Diabetologica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Diabetologica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00592-025-02523-1\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Diabetologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00592-025-02523-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

目的:评估慢性多种药物的趋势,并确定居住在意大利伦巴第地区的人群中多种药物暴露的预测因素。方法:使用一个行政健康数据库,我们确定了2010年至2022年期间65-90岁的糖尿病(DM)患者接受降糖药物治疗。采用Cochran-Armitage趋势检验评估慢性多药倾向。采用调整后的logistic回归模型分析多种药物暴露的预测因素。结果:老年糖尿病患者人数从2010年的243160人增加到2022年的314238人。多种药物暴露的患病率从2010年的13.8%上升到2013年的15.8%,随后从2014年开始下降。值得注意的是,2020年,患病率降至11.8%,2021年进一步降至9.1%,2022年再次上升至11.7%。我们还观察到,随着时间的推移,推荐的抗高血糖药物的使用增加了。多种药物暴露的重要预测因素包括高龄、女性、合并症、DPP-4i、GLP-1-RA、胰岛素和SGLT2-i的使用。结论:在研究后期观察到的多重用药减少可能反映了老年糖尿病患者管理的改善,与推荐的治疗方法一致,特别是对那些高风险的多重用药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Polypharmacy in older patients with diabetes mellitus: a population based-study of northern Italy.

Aims: To evaluate the trends in chronic polypharmacy and identify predictors of polypharmacy exposure in a population residing in Lombardy region of Italy.

Methods: Using an administrative health database, we identified individuals aged 65-90 years with diabetes mellitus (DM) treated with antihyperglycemic drugs from 2010 to 2022. The trend of chronic polypharmacy was assessed using the Cochran-Armitage trend test. An adjusted logistic regression model was employed to analyze predictors of polypharmacy exposure.

Results: The number of older patients with DM increased from 243,160 in 2010 to 314,238 in 2022. The prevalence of polypharmacy exposure rose from 13.8% in 2010 to 15.8% in 2013, followed by a decline starting in 2014. Notably, in 2020, the prevalence dropped to 11.8%, further decreasing to 9.1% in 2021, before rising again to 11.7% in 2022. We also observed an increased use of recommended antihyperglycemic drugs over time. Significant predictors of polypharmacy exposure included advanced age, female sex, comorbidities, and use of DPP-4i, GLP-1-RA, insulin, and SGLT2-i.

Conclusions: The observed decrease in polypharmacy in the latter years of the study period may reflect improvements in the management of older patients with DM, aligning with recommended therapies, particularly for those at higher risk of polypharmacy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Diabetologica
Acta Diabetologica 医学-内分泌学与代谢
CiteScore
7.30
自引率
2.60%
发文量
180
审稿时长
2 months
期刊介绍: Acta Diabetologica is a journal that publishes reports of experimental and clinical research on diabetes mellitus and related metabolic diseases. Original contributions on biochemical, physiological, pathophysiological and clinical aspects of research on diabetes and metabolic diseases are welcome. Reports are published in the form of original articles, short communications and letters to the editor. Invited reviews and editorials are also published. A Methodology forum, which publishes contributions on methodological aspects of diabetes in vivo and in vitro, is also available. The Editor-in-chief will be pleased to consider articles describing new techniques (e.g., new transplantation methods, metabolic models), of innovative importance in the field of diabetes/metabolism. Finally, workshop reports are also welcome in Acta Diabetologica.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信